Dr. Marcin Kortylewski focuses on the development of novel oligonucleotide-based cancer immunotherapies. His research identified for the first time that STAT3 is a master regulator of tumor immune evasion and later described role of STAT3 as a driver of cancer resistance to radiation therapy. Dr. Kortylewski invented an oligonucleotide delivery platform aimed at tumor-associated myeloid cells and the undruggable transcriptional regulators of immune cell functions. Dr. Kortylewski was the Co-founder of Olimmune, a company acquired by Scopus BioPharma in June 2021.
He received his MS in biotechnology from Adam Mickiewicz University and his Ph.D. in molecular biology from the Poznań University of Medical Sciences in Poznań, Poland. Dr. Kortylewski completed postdoctoral training in RWTH Aachen in Germany and later at H. Lee Moffitt Cancer Center in Tampa, Florida.
Dr. Kortylewski is currently a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Comprehensive Cancer Center. He serves on the Faculty Executive Committee and as a Scientific Co-Leader for the Head & Neck Disease Team. His research earned him an Outstanding New Investigator Award from the American Society of Gene & Cell Therapy (2016) and notable funding from major federal and private sources, such as NIH/NCI, Department of Defense (DoD), and Prostate Cancer Foundation. He is an Associate Editor-In-Chief of Molecular Therapy-Nucleic Acids (Cell Press) and serves on grant review panels at the NIH, NFCR, DoD as well as private foundations. He is an author of over 80 research publications and an inventor on 15 patents and patent applications.